title: Decreased insulin secretion in patients receiving tacrolimus as GVHD prophylaxis after allogeneic hematopoietic SCT.
authors: S
authors: S
authors: Fuji
authors: S-W
authors: SW
authors: Kim
authors: S
authors: S
authors: Mori
authors: K
authors: K
authors: Furuta
authors: R
authors: R
authors: Tanosaki
authors: Y
authors: Y
authors: Heike
authors: Y
authors: Y
authors: Takaue
authors: T
authors: T
authors: Fukuda
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006706:Homeostasis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007328:Insulin / Q000276:immunology / Q000378:metabolism*; D007333:Insulin Resistance; D000078790:Insulin Secretion; D008875:Middle Aged; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D016559:Tacrolimus / Q000627:therapeutic use*; D014184:Transplantation, Homologous
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007166:Immunosuppressive Agents; D007328:Insulin; D016559:Tacrolimus